Current Report Filing (8-k)
February 16 2021 - 5:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
February 16, 2021
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On February 16, 2021, Elite Pharmaceuticals,
Inc. (“Elite” or the “Company”) filed its quarterly report on Form 10-Q for the quarter ended December
31, 2020 and, thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release
is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company
will host a conference call at 11:30 AM Eastern Standard Time (EST) on Wednesday, February 17, 2021, to provide a general business
update. Elite will respond to various stockholder questions submitted prior to the call.
Conference Call Information
Date:
|
February 17, 2021
|
Time:
|
11:30 AM EST
|
Dial- in numbers:
|
1-800-346-7359 (domestic)
1-973-528-0008 (international)
|
Conference number:
|
98840
|
Questions:
|
dianne@elitepharma.com
Financial questions by 7:00 PM EST on Tuesday, February 16, 2021
|
Audio Replay:
|
https://elite.irpass.com/events_presentations
|
Item 7.01 Regulation FD Disclosure.
The information disclosed in Item 2.02 above is incorporated
into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished
under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure”
and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein
shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference
into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language
in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the
exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy
the requirements of Regulation FD.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 16, 2021
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
2
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Sep 2023 to Sep 2024